- Home
- OCEAW vs RILYP Comparison
OCEAW vs RILYP Comparison
Compare OCEAW & RILYP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEAW
- RILYP
- Stock Information
- Founded
- OCEAW N/A
- RILYP 1973
- Country
- OCEAW United States
- RILYP United States
- Employees
- OCEAW 7
- RILYP N/A
- Industry
- OCEAW Biotechnology: Pharmaceutical Preparations
- RILYP Investment Managers
- Sector
- OCEAW Health Care
- RILYP Finance
- Exchange
- OCEAW Nasdaq
- RILYP Nasdaq
- Market Cap
- OCEAW N/A
- RILYP N/A
- IPO Year
- OCEAW 2021
- RILYP N/A
- Fundamental
- Price
- OCEAW $0.03
- RILYP $4.01
- Analyst Decision
- OCEAW
- RILYP
- Analyst Count
- OCEAW 0
- RILYP 0
- Target Price
- OCEAW N/A
- RILYP N/A
- AVG Volume (30 Days)
- OCEAW N/A
- RILYP 20.5K
- Earning Date
- OCEAW N/A
- RILYP 01-01-0001
- Dividend Yield
- OCEAW N/A
- RILYP 30.91%
- EPS Growth
- OCEAW N/A
- RILYP N/A
- EPS
- OCEAW N/A
- RILYP N/A
- Revenue
- OCEAW N/A
- RILYP $854,383,000.00
- Revenue This Year
- OCEAW N/A
- RILYP N/A
- Revenue Next Year
- OCEAW N/A
- RILYP N/A
- P/E Ratio
- OCEAW N/A
- RILYP N/A
- Revenue Growth
- OCEAW N/A
- RILYP N/A
- 52 Week Low
- OCEAW N/A
- RILYP $3.28
- 52 Week High
- OCEAW N/A
- RILYP $20.49
- Technical
- Relative Strength Index (RSI)
- OCEAW N/A
- RILYP 39.50
- Support Level
- OCEAW N/A
- RILYP $3.84
- Resistance Level
- OCEAW N/A
- RILYP $4.93
- Average True Range (ATR)
- OCEAW 0.00
- RILYP 0.79
- MACD
- OCEAW 0.00
- RILYP -0.07
- Stochastic Oscillator
- OCEAW 0.00
- RILYP 5.45
Stock Price Comparison Chart: OCEAW vs RILYP
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
About RILYP B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.